A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://www.ncbi.nlm.nih.gov/pubmed/24373380
http://dx.doi.org/10.1186/1471-2407-13-613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://www.ncbi.nlm.nih.gov/pubmed/24373380
http://dx.doi.org/10.1186/1471-2407-13-613

Ejemplares similares